FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Regulation and HHS Policy Holt Law FDA mulls compounding for peptides previously flagged over safety risks BioSpace Alternative Treatments: Identifying Options After FDA Reclassification of Specific Peptides Bergen Total Health Buy BPC 157 2 Day Shipping 99%+ Nextday Peptides